These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

262 related items for PubMed ID: 17582695

  • 21. A possible haemodynamic mechanism for amyotrophic lateral sclerosis.
    Arhart RW.
    Med Hypotheses; 2010 Oct; 75(4):341-6. PubMed ID: 20400230
    [Abstract] [Full Text] [Related]

  • 22. The neuropeptide genes TAC1, TAC3, TAC4, VIP and PACAP(ADCYAP1), and susceptibility to multiple sclerosis.
    Cunningham S, O'Doherty C, Patterson C, McDonnell G, Hawkins S, Marrosu MG, Vandenbroeck K.
    J Neuroimmunol; 2007 Feb; 183(1-2):208-13. PubMed ID: 17175032
    [Abstract] [Full Text] [Related]

  • 23. Pituitary adenylate cyclase-activating polypeptide, vasoactive intestinal polypeptide and their receptors: distribution and involvement in the secretion of Podarcis sicula adrenal gland.
    Valiante S, Prisco M, Sciarrillo R, De Falco M, Capaldo A, Gay F, Andreuccetti P, Laforgia V, Varano L.
    J Endocrinol; 2008 Feb; 196(2):291-303. PubMed ID: 18252952
    [Abstract] [Full Text] [Related]

  • 24. cAMP activation by PACAP/VIP stimulates IL-6 release and inhibits osteoblastic differentiation through VPAC2 receptor in osteoblastic MC3T3 cells.
    Nagata A, Tanaka T, Minezawa A, Poyurovsky M, Mayama T, Suzuki S, Hashimoto N, Yoshida T, Suyama K, Miyata A, Hosokawa H, Nakayama T, Tatsuno I.
    J Cell Physiol; 2009 Oct; 221(1):75-83. PubMed ID: 19496170
    [Abstract] [Full Text] [Related]

  • 25. VIP- and PACAP-mediated immunomodulation as prospective therapeutic tools.
    Pozo D.
    Trends Mol Med; 2003 May; 9(5):211-7. PubMed ID: 12763526
    [Abstract] [Full Text] [Related]

  • 26. [The role for oxidative stress in neurodegenerative diseases].
    Shibata N, Kobayashi M.
    Brain Nerve; 2008 Feb; 60(2):157-70. PubMed ID: 18306664
    [Abstract] [Full Text] [Related]

  • 27. PACAP and VIP prevent apoptosis in schwannoma cells.
    Castorina A, Tiralongo A, Giunta S, Carnazza ML, Rasi G, D'Agata V.
    Brain Res; 2008 Nov 19; 1241():29-35. PubMed ID: 18835258
    [Abstract] [Full Text] [Related]

  • 28. The secretin G-protein-coupled receptor family: teleost receptors.
    Cardoso JC, Clark MS, Viera FA, Bridge PD, Gilles A, Power DM.
    J Mol Endocrinol; 2005 Jun 19; 34(3):753-65. PubMed ID: 15956345
    [Abstract] [Full Text] [Related]

  • 29. The (endo)cannabinoid system in multiple sclerosis and amyotrophic lateral sclerosis.
    Centonze D, Rossi S, Finazzi-Agrò A, Bernardi G, Maccarrone M.
    Int Rev Neurobiol; 2007 Jun 19; 82():171-86. PubMed ID: 17678961
    [Abstract] [Full Text] [Related]

  • 30. Distribution and functional characterization of pituitary adenylate cyclase-activating polypeptide receptors in the brain of non-human primates.
    Jolivel V, Basille M, Aubert N, de Jouffrey S, Ancian P, Le Bigot JF, Noack P, Massonneau M, Fournier A, Vaudry H, Gonzalez BJ, Vaudry D.
    Neuroscience; 2009 May 05; 160(2):434-51. PubMed ID: 19236905
    [Abstract] [Full Text] [Related]

  • 31. [Function of glial G-protein coupled receptors].
    Furuta A, Wada E, Wada K.
    Brain Nerve; 2007 Jul 05; 59(7):717-24. PubMed ID: 17663142
    [Abstract] [Full Text] [Related]

  • 32. The neuropeptide pituitary adenylate cyclase activating polypeptide modulates Ca2+ and pro-inflammatory functions in human monocytes through the G protein-coupled receptors VPAC-1 and formyl peptide receptor-like 1.
    El Zein N, Badran B, Sariban E.
    Cell Calcium; 2008 Mar 05; 43(3):270-84. PubMed ID: 17651798
    [Abstract] [Full Text] [Related]

  • 33. Modulation of AMPA receptor-mediated ion current by pituitary adenylate cyclase-activating polypeptide (PACAP) in CA1 pyramidal neurons from rat hippocampus.
    Costa L, Santangelo F, Li Volsi G, Ciranna L.
    Hippocampus; 2009 Jan 05; 19(1):99-109. PubMed ID: 18727050
    [Abstract] [Full Text] [Related]

  • 34. VIP and PACAP receptor pharmacology: a comparison of intracellular signaling pathways.
    Dickson L, Aramori I, Sharkey J, Finlayson K.
    Ann N Y Acad Sci; 2006 Jul 05; 1070():239-42. PubMed ID: 16888173
    [Abstract] [Full Text] [Related]

  • 35. The endocannabinoid system in the inflammatory and neurodegenerative processes of multiple sclerosis and of amyotrophic lateral sclerosis.
    Rossi S, Bernardi G, Centonze D.
    Exp Neurol; 2010 Jul 05; 224(1):92-102. PubMed ID: 20353778
    [Abstract] [Full Text] [Related]

  • 36. Postulated vasoactive neuropeptide autoimmunity in fatigue-related conditions: a brief review and hypothesis.
    Staines DR.
    Clin Dev Immunol; 2006 Mar 05; 13(1):25-39. PubMed ID: 16603442
    [Abstract] [Full Text] [Related]

  • 37. Neuroprotection: a comparative view of vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide.
    Brenneman DE.
    Peptides; 2007 Sep 05; 28(9):1720-6. PubMed ID: 17513014
    [Abstract] [Full Text] [Related]

  • 38. Immunomodulatory roles of VIP and PACAP in models of multiple sclerosis.
    Abad C, Waschek JA.
    Curr Pharm Des; 2011 Sep 05; 17(10):1025-35. PubMed ID: 21524252
    [Abstract] [Full Text] [Related]

  • 39. Are there causal relationships between the development of the inflammatory diseases amyotrophic lateral sclerosis and asthma?
    Menendez A, Kuffler D.
    P R Health Sci J; 2006 Mar 05; 25(1):51-66. PubMed ID: 16883679
    [Abstract] [Full Text] [Related]

  • 40. Genetic association of vasoactive intestinal peptide receptor with rheumatoid arthritis: altered expression and signal in immune cells.
    Delgado M, Robledo G, Rueda B, Varela N, O'Valle F, Hernandez-Cortes P, Caro M, Orozco G, Gonzalez-Rey E, Martin J.
    Arthritis Rheum; 2008 Apr 05; 58(4):1010-9. PubMed ID: 18383379
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 14.